Molecularly Targeted Therapeutic Approved for Another Type of Non-Hodgkin Lymphoma
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
Progress Against Cancer
The FDA expanded the use of a targeted therapy for a form of non-Hodgkin lymphoma called marginal zone lymphoma.
An immune checkpoint inhibitor – a form of immunotherapy – has had its use expanded for use in the treatment of bladder cancer.
The FDA approved a molecularly targeted therapeutic for women with advanced ovarian cancer linked to a BRCA gene mutation.
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
The FDA approved a molecularly targeted therapeutic for treating certain patients with soft tissue sarcoma.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with head and neck cancer.
The FDA approved a liquid biopsy – a test that uses a blood sample – to identify patients with metastatic non-small cell lung cancer.
The May 2016 approval of atezolizumab provided the first new treatment in more than 30 years for patients with the most common type of bladder cancer.
The FDA expanded the use of an immunotherapeutic to include certain patients with Hodgkin lymphoma. Learn more about this approval.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More